Dosing JAK Inhibitors in Patients With Myelofibrosis


For most JAK inhibitors dosing starts at the maximum safe dose, while ruxolitinib often requires lower initial doses and dose reductions over the first 12 weeks when cytopenias typically worsen before partially improving, warranting consideration of earlier switching to alternative JAK inhibitors instead of pushing through transfusions.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.